Completed PHASE2 INTERVENTIONAL 1-arm NCT01412892

Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas (NFitor)

A Single Arm, Multicenter Phase II a Trial of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas That Cannot be Removed by Surgery

Sponsor: Assistance Publique - Hôpitaux de Paris

Conditions Neurofibromatoses Neurofibromatosis Type 1 Plexiform Neurofibroma

Interventions RAD001: Everolimus

Updated 6 times since 2017 Last updated: Nov 13, 2014 Started: Apr 30, 2011 Primary completion: Oct 31, 2013 Completion: Oct 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Neurofibromatoses and Neurofibromatosis Type 1 and is currently completed. Assistance Publique - Hôpitaux de Paris leads this study, which shows 6 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Apr 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Assistance Publique - Hôpitaux de Paris
Novartis

Data source: Assistance Publique - Hôpitaux de Paris

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Créteil, France